Insulin degludec/insulin aspart (IDegAsp) is the first soluble co-formulation which combines two insulin analogues, and provides effective basal and prandial glycemic coverage. It has been assessed as basal insulin in type 2 diabetes mellitus (T2DM), and as part of basal-bolus regime in both type 1 diabetes mellitus and T2DM. Insulin degludec has also been assessed as flexibly administered basal insulin in terms of time of administration. This review discusses data pertaining to the efficacy, safety, tolerability, and clinical potential of IDegAsp.
Insulin degludec/insulin aspart (IDegAsp) is a recently developed soluble co-formulation containing two insulin analogues: 30% of short-acting analogue IAsp and 70% basal analogue IDeg. In a model of the subcutaneous environment [10] , IDeg forms distinct multi-hexamers that are slowly absorbed, while IAsp immediately forms monomers that are rapidly absorbed. This indicates that the basal (IDeg) and prandial (IAsp) components do not interact and their distinct pharmacokinetic/pharmacodynamics profiles are not compromised by coformulation [11] .
This review discusses currently available evidence related to this novel co-formulation, and describes its future potential.
CLINICAL TRIAL PROGRAMME
The IDegAsp clinical trial programme builds upon the extensive studies conducted for IDeg.
IDeg has been studied in phase 3a and 3b trials, conducted in both type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) subjects [12, 13] . It has been assessed as basal insulin in T2DM, and as part of basal-bolus regime in both T1DM and T2DM [13, 14,] . IDeg has also been assessed as flexibly administered basal insulin in terms of time of dosages [15, 16] .
The IDegAsp clinical trial programme, named BOOST (clinical trial number: 3594), studied this molecule in T1DM, comparing it with a basal-bolus regime [17] . In T2DM,
IDegAsp once daily has been analysed as an initiation as well as intensification strategy [18, 19] . IDegAsp twice daily has also been studied as an intensification treatment in T2DM insulin users [20, 21] . Results published from various studies in the BOOST family provide an overview of this novel soluble co-formulation insulin analogue.
COMPARISON WITH BASAL INSULIN
In a 16-week-long, open-label, randomised controlled trial, once-daily IDegAsp was compared with IGlar, both combined with metformin [18] .
This treat-to-target study aimed to achieve a primary fasting plasma glucose (FPG) target of 4.0-6.0 mmol/L, and a secondary target postdinner plasma glucose of \8.0 mmol/L, provided that no hypoglycemic episode had taken place. A starting dose of 10 U/day of insulin was used [18] .
There was a third arm which assessed an alternative formulation, this has since been withdrawn from development. Both IDegAsp arms achieved 0.11% higher HbA1c reduction vs. IGlar; however, this was not statistically significant. A similar proportion of subjects was able to achieve target HbA1c without confirmed hypoglycemia in the last 4 weeks of the trail [18] . This can be explained by slightly better FPG reduction with IDegAsp as compared to IGlar (mean difference 0.13 mmol/L). IDegAsp was able to achieve a lower post-dinner glucose increment than IGlar (0.13 vs. this study, which uses novel, modern CGM technology, are consistent with those obtained from 9-point SMPG in the parent study [22] . The lack of postprandial glucose increment with IDegAsp, however, drives home the utility of adding a prandial or rapid-acting component to basal insulin. Demonstration of uniform glycemic response at night, without increasing the risk of hypoglycemia, is reassuring [22] .
Onishi et al. [19] published data from a study conducted in Japanese subjects. In this treat to target protocol, 296 insulin-naïve adults with T2DM discontinued all sulfonylureas, glinides and dipeptidyl peptidase 4 inhibitors, while continuing other oral antihyperglycemic drugs after being randomised to initiate either IDegAsp or IGlar with a starting dose of 10 U/ day. IDegAsp was injected just prior to the largest meal of the day (chosen at discretion of the subject) while IGlar was taken at a fixed time daily, either before breakfast or at bedtime. [20] was not seen in this study. The benefit of weight reduction seen in Fulcher et al. [20] was also not evident.
USE IN TYPE 1 DIABETES
IDegAsp has also been studied in people with T1DM. It maintains its distinct prandial and basal pharmacodynamics in elderly subjects (age C65 years) [24, 25] . In a 26-week-long, phase 3 randomised, open-label, treat-to-target trial, IDegAsp was prescribed once daily at any meal, with IAsp at other meals, creating an innovative three dose regime. This was compared with a standard basal-bolus regime using three doses of aspart and one or two doses of detemir per day. The IDegAsp basal regime was non-inferior to the standard basal-bolus regime in terms of HbA1c reduction, though it had a 13% lower dose requirement (69 U and 0.86 U/kg vs. IDet 79 U and 1.00 U/kg; P\0.0001) [17] . It was also associated with Though not studied yet, it creates the hope for use of a convenient regime, using two doses of IDegAsp, in persons with T1DM, who currently have to take 4-5 injections per day with conventional insulins [18] . Such a regime will also be useful for patients with T2DM, who require intensification with basal-bolus therapy, but do not wish to take multiple injections.
CLINICAL POTENTIAL
IDegAsp has demonstrated its utility in the management of both T1DM and T2DM. In T1DM, it heralds the beginning of an era of convenient, effective three dose regime, which will replace currently used four or five dose based intensive therapies. In T2DM, it offers the advantage of lower hypoglycemia, and greater safety [16, 17] . This is achieved with lesser or equal dose requirement. This advantage will allow IDegAsp to be used as insulin of choice while initiating therapy. Current American Diabetes Association (ADA)/European Association for study of Diabetes (EASD) guidelines recommend only basal insulin for this purpose, citing the ''inconvenience'', lack of flexibility, and risk of hypoglycemia associated with conventional premixed insulins [20] .
IDegAsp overcomes these arguments against the use of premixed insulin. It is convenient and flexible to use, as it can be administered with any major meal, irrespective of time. It can also be used once daily or twice daily, with a reduced risk of hypoglycemia than currently available insulin [16, 17] . It has been studied in combination with various oral antihyperglycemic drugs [15] .
Though not yet approved in the United States, IDeg is an approved drug in Europe, Japan Mexico, India, and other countries as well.
The definition of hypoglycemia of 3.1 mmol/ L (56 mg/dL) and the FPG targets of 4-5 mmol/L (71-89 mg/dL) used in the phase 3a clinical development is debatable [14] [15] [16] [17] 60-70% of the total daily insulin requirements in combination with short-/rapid-acting insulin at the remaining meals followed by individual dosage adjustments [21] . It is recommended that titration should be based upon monitoring of plasma glucose: the morning dose requirement of IDegAsp may be lower than the dinner dose. Switching from twice daily premixed insulin to two doses of IDegAsp should prompt a 10-20% reduction in initial dose (Table 1) . A patient centric approach should be followed while choosing initial doses and up-titrating them. 
